Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0LU9X
|
|||
Drug Name |
Tetra-hydro-oxazolopyridine derivative 3
|
|||
Synonyms |
PMID28067079-Compound-63
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
DAINIPPON SUMITOMO PHARMA CO., LTD
|
|||
Structure |
Download2D MOL |
|||
Formula |
C18H12ClF2N3O2
|
|||
Canonical SMILES |
C1CN(CC2=C1OC(=N2)C3=NC=C(C=C3)F)C(=O)C4=CC(=CC(=C4)Cl)F
|
|||
InChI |
1S/C18H12ClF2N3O2/c19-11-5-10(6-13(21)7-11)18(25)24-4-3-16-15(9-24)23-17(26-16)14-2-1-12(20)8-22-14/h1-2,5-8H,3-4,9H2
|
|||
InChIKey |
CHAFCAFCZBTARK-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Metabotropic glutamate receptor 5 (mGluR5) | Target Info | Modulator | [1] |
Target's Patent Info | Metabotropic glutamate receptor 5 (mGluR5) | Target's Patent Info | [1] | |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Gap junction | ||||
Long-term potentiation | ||||
Retrograde endocannabinoid signaling | ||||
Glutamatergic synapse | ||||
Huntington's disease | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
Metabotropic glutamate receptor group III pathway | ||||
Metabotropic glutamate receptor group I pathway | ||||
Endogenous cannabinoid signaling | ||||
Reactome | G alpha (q) signalling events | |||
Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
WikiPathways | Hypothetical Network for Drug Addiction | |||
GPCRs, Class C Metabotropic glutamate, pheromone | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.